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BACKGROUND: Acute postoperative pain is common after most surgical procedures.
Despite the availability of many analgesic options, postoperative pain management
is often unsatisfactory. Purified capsaicin (ALGRX 4975 98% pure) has demon-
strated prolong inhibition of C-fiber function in in vitro, preclinical, and clinical
studies, and may be an effective adjunct to postoperative pain management.
METHODS: We performed a single-center, randomized, double-blind, placebo-
controlled study of the analgesic efficacy of a single intraoperative wound
instillation of 1000 g ultrapurified capsaicin (ALGRX 4975) after open mesh groin
hernia repair in 41 adult male patients. The primary end-point was average daily
visual analog scale (VAS) pain scores during the first week after surgery assessed
as area under the curve (AUC). Pain was recorded twice daily in a pain diary for
4 wk. Physical examination and laboratory tests were done before and 1 wk after
surgery, together with recordings of adverse events up to 28 days. Adverse events
were recorded. Data were also analyzed using a mixed-effects analysis with
NONMEM.
RESULTS: VAS AUC was significantly lower during the first 3 days postoperatively
(P  0.05), but not for the whole 1 or 4 wk postoperatively. Mixed-effects analysis
with NONMEM revealed that pain scores were significantly lower (P 0.05) in the
capsaicin group during the first 4 days. No clinically significant serious adverse
events were observed, although a mild transient increase in liver enzymes was seen
more often in the capsaicin-treated group.
CONCLUSION: In the setting of a well-defined analgesic protocol standard, VAS AUC
analysis and a mixed-effect analysis showed superior analgesia of capsaicin relative
to placebo during the first 3–4 days after inguinal hernia repair.
(Anesth Analg 2008;107:282–91)
Adult groin hernia surgery is one of the most
common operations, with an annual rate of approxi-
mately 2800 per million in the United States.1 Al-
though there is little intraoperative morbidity, acute
postoperative pain has been shown to be the most
prominent factor in extending recovery and delaying
return to everyday functions.2–6 Present evidence-
based analgesic therapy combines infiltration with local
anesthetics, systemic nonsteroidal antiinflammatory
drugs or cyclooxygenase-2 inhibitors, acetaminophen,
and opioids for rescue pain management.* Despite this
multimodal approach, analgesia is often unsatisfactory.7
ALGRX 4975 is a novel, long-acting, non-opioid
analgesic for moderate to severe pain. The active
ingredient in ALGRX 4975 is ultrapurified natural
capsaicin, which is known for the ability to induce
stinging and burning algesia.8 Ultrapurification is
accomplished using high-pressure liquid chromatog-
raphy. This process removes dihydrocapsaicin and
other capsaicinoids, resulting in 98% pure capsaicin.
Repetitive or intense exposure to capsaicin results in a
selective, reversible loss of nociceptive nerve endings
(C-fibers).9 This ability to induce reversible long last-
ing nociceptor inhibition makes capsaicin a potentially
useful topical analgesic. Volunteer studies have
shown that nociceptive C-fiber regeneration occurs
within 4–16 wk, adequate to provide analgesia for the
full period of recovery after surgery.9–11
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We designed this single-center, double-blind,
parallel-group, placebo-controlled, randomized trial
of the analgesic efficacy of a single wound instillation
of 1000 g ultrapurified capsaicin (ALGRX 4975)
during open groin hernia repair, to test the primary
hypothesis that capsaicin would provide superior
analgesia during the first week after surgery.
METHODS
This phase two, single-center, randomized, double-
blind, placebo-controlled, parallel-group study was
approved by the Danish Medicines Agency, the local
ethics committee, and data handling authorities, and
monitored according to the principles of Good Clinical
Practice by a clinical research organization (Norma,
Hørsholm, Denmark). The trial was registered with
www.ClinicalTrials.gov (NCT00146198) before enroll-
ment. After providing written informed consent, 42
adult male patients from an ambulatory hernia clinic
scheduled to undergo Lichtenstein mesh repair of an
inguinal hernia were enrolled in the study. Inclusion
criteria were: male 18–70-yr-of-age, primary groin her-
nia planned to undergo Lichtenstein mesh repair, ability
to use pain scales, ASA class I or II based upon medical
history, physical examination, and screening laboratory
results, willing to take oral pain medication (acetamino-
phen, ibuprofen) for the first week, and willing to fill out
a diary for 4 wk after surgery. Exclusion criteria were as
follows: a previous lower abdominal surgical procedure,
presently taking bupivacaine, acetaminophen, ibupro-
fen, or tramadol, a medical condition likely to alter
wound healing or pain ratings, systolic blood pressure
more than 150 or diastolic more than 95 mm Hg,
contraindication to general anesthesia, bilateral hernia
repair, a history of drug or alcohol abuse within the past
2 yr, use of antihypertensive, antidepressant, or psycho-
tropic drugs that has not been stable for 3 mo, and use of
an investigational drug within 3 mo or scheduled to
receive an investigational drug other than ALGRX 4975
during the study period.
Current use of the followingdrugs resulted in exclusion:
digoxin, antiarrhytmics except -blockers, warfarin, the-
ophylline, aminoglycosides, anticonvulsants, except benzo-
diazepines or lithium, pain medication, or central nervous
system active drugs. Small-dose aspirin for cardiovascular
protection was allowed.
Study Design
Screening Phase: One to 2 wk before surgery,
patients were screened for eligibility by a physical
examination including all major organ systems, arte-
rial blood pressure, heart rate, and electrocardiogram
(ECG). A standard hematology panel (complete blood
count and differential count), a standard clinical
chemistry panel, and a standard urine analysis panel
with microscopic examination (only if dipstick was
positive) were performed.
Blinding, Randomization, and Study Medication
The active study medication was purified (98%)
capsaicin (ALGRX 4975, Anesiva, Inc., South San
Francisco, USA). Based upon safety and efficacy data
from pilot studies,12–15 an instillation of 1000 g
purified capsaicin was chosen. Purified capsaicin was
supplied as an open-label stock solution, and diluted
with water for a maximum of 4 h before administra-
tion. Placebo (water) and capsaicin (both 15 mL after
dilution) were colorless and odorless. Each patient
was given a unique randomization number in the
order they entered the study. This number was linked
to a computer-randomized treatment sequence only
known to two study nurses who prepared the study
medication. The randomization code was generated to
ensure that the appropriate number of subjects was
randomly allocated to each treatment group, with a
minimum of 20 in each group. A labeled vial of blinded
study medication was handed to the investigator by the
unblinded study nurse. During the study, the subject
and the investigators/study staff were blinded to the
study drug. In case of an emergency, separately blinded
envelopes for each study subject were available for the
investigator and the medical monitor.
Surgery and Anesthesia
A Lichtenstein mesh hernia repair was performed
with the patient under general anesthesia. Anesthesia
was induced with propofol 2–3 mg/kg, and remifen-
tanil 0.5–1.0 g  kg1  min1. Anesthesia was main-
tained with a propofol infusion of 0.3–0.6
mg  kg1  h1 and a remifentanil infusion of 0.3–1.0
g  kg1  min1. Near the end of the repair, a com-
bined local infiltration and ilioinguinal nerve block16
using 40 mL 0.25% bupivacaine was administered at
least 10 min before the instillation of capsaicin or
placebo. After suturing of the mesh, capsaicin or
placebo was instilled for at least 1 min and left to
dwell for 5 min, taking care to include the whole of the
open wound from the subcutaneous layer down to the
mesh, but not the surrounding skin. The wound was
then closedwith the capsaicin or placebo instilled. At the
end of surgery, fentanyl 1.5 g/kg was administered IV.
Postoperative Management
Pain was assessed in the postanesthesia pain unit,
as described below. The patient was discharged 4 h
postoperatively if a family member could be present
for the first postoperative night. Otherwise the patient
stayed in the hospital until the next morning. Before
discharge, instructions regarding the pain diary were
given to the patient and family member.
First Postoperative Day
A telephone call regarding pain and general well-
being was made.
One Week Postoperatively
The patient was seen at the hospital and a physical
examination, ECG, urine, and blood test similar to that
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of the screening day were performed. Sutures were
removed and the wound was evaluated. Adverse
events (AEs) were recorded. The patient’s pain diary
was collected together with any acetaminophen, ibu-
profen, or tramadol tablets not used.
Weeks 2 and 4
A telephone call regarding wound healing, analge-
sic efficacy, and AEs was made. At the 4-wk interview,
the patients returned the pain diary in a prestamped
envelope.
Pain Medication
According to our usual practice, patients were
given the following pain medication for the first
postoperative week; acetaminophen 1 g every 6 h and
ibuprofen 600 mg every 8 h. Supplemental medication
was tramadol 50 mg to be taken as needed (4–6 h
apart maximum 200 mg daily). Pain medication was
recorded in the diary. After 1 wk, all excess pain
medicine was collected and compared with the diary
recordings. Any need for pain medication beyond the
first week was recorded in the diary for weeks 2–4.
AEs and Safety Analysis
Any untoward medical occurrence to a patient
during the study (from randomization to 4 wk post-
operatively) was recorded as an AE. This included any
unfavorable and unintended sign including abnormal
laboratory findings, symptoms, disease, injuries, ad-
verse reactions, or exacerbations of preexisting ill-
nesses. Laboratory findings were classified as above or
below the normal range (age corrected).
Pain Recording
Pain ratings were recorded on a horizontal 100 mm
Visual Analog Scale (VAS). Patients were instructed in
the use of the scale at the screening visit, on the day of
surgery, and on the day after surgery. Pain at rest and
when rising from prone to sitting was recorded at the
screening visit. Pain was recorded immediately after
awakening from surgery and 4 h postoperatively. To
standardize pain measurements, movement-associated
pain from the wound when getting out of bed in the
morning and getting into bed at night was recorded for
4 wk postoperatively in a pain diary.
Outcomes
The primary end-point was average daily VAS
scores, assessed during movement upon arising in the
morning and retiring in the evening, during the first
week after surgery. Pain scores during the first week
were chosen as a primary outcome based upon pilot
studies12–15 and the theoretical duration of c-fiber
inhibition,9 assuming high pain score in this period as
seen in previous groin hernia studies.4 Secondary
end-points included: time to supplemental medication
usage, average pain scores at individual intervals for
the first 4 wk after surgery, area under the curve
(AUC) pain scores from 4 h postoperatively to day 7
evening (AUCday 7), AUC during the first 4 wk after
surgery (AUCweek 4), and when (day and time) the AUC
pain scores were no longer significantly different.
Statistics
A sample size of 20 per treatment group was
planned in this study. This sample size would have
80% power to detect 24 mm treatment difference in
pain VAS score at a 5% significance level, assuming
the standard deviation of 26 mm. VAS pain scores are
presented as medians with the 25th and 75th percen-
tiles. We calculated AUC according to the trapezoidal
rule17 to obtain a summary measure and to analyze
the differences in response between the purified cap-
saicin and placebo groups. The time point immedi-
ately after surgery was not included in the AUC
calculations since not all patients were able to cooper-
ate in giving a pain score at that time. Since the AUC
pain scores were skewed and not normalized by
logarithmic transformation, nonparametric testing
was performed using Wilcoxon’s signed rank test to
compare groups. Differences in frequencies were com-
pared using Fischer’s exact test. P values 0.05 are
considered statistically significant.
To control the assumption about the inter- and
intraindividual variability across the VAS observation
and its influence on statistical decision making, we
also performed a post hoc nonparametric analysis of
the VAS scores using nonlinear mixed effect modeling
program NONMEM VI (Globomax LLC, Hanover,
MD). The model parameters were typical VAS scores
each postoperative day, and drug effect (if any), as
described in Appendix.
RESULTS
Forty-two patients were randomized, of whom 41
who were treated received capsaicin or placebo. One
patient was excluded before instillation of the study
medication because no hernia was found during sur-
gery and a herniorrhaphy was not performed. The two
groups were similar regarding age, body mass index,
preoperative pain, side of hernia, anesthesia time, and
duration of surgery. Use of pain medication was the
same in both treatment groups, with an equal amount
of acetaminophen and ibuprofen taken during the
entire duration of the study (Table 1).
VAS Pain Scores
The time course of pain throughout the study is
shown in Figure 1. Inspection of the VAS scores shows
a rapid decline in VAS score for both groups in the
first days after surgery, as well as considerable inter-
subject variability in VAS scores. The average median
VAS pain scores in the first week after surgery were
10.3 mm/d in the capsaicin group, and 13.9 mm/d in
the placebo group (P  0.43). Similarly, the average
median VAS scores for weeks 1–4 after surgery were 3.8
mm/d in the capsaicin group, and 6.0 mm/d in the
placebo group, P  0.89. AUC pain scores for the first
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week or the whole study were also not significantly
different (P  0.25 and 0.78, respectively).
However, a significant difference in the AUC
favoring capsaicin was seen for the time period from
4 h until the morning of the third day postsurgery
(AUC4h – day 3 morn, P  0.045), which appears
consistent with the time course of median VAS pain
scores shown in Figure 1. The differences in the
distribution of VAS pain scores during the first 4
days are further evaluated in boxplots (Fig. 2),
which illustrate lower pain scores at every time
point in the capsaicin group compared with placebo
as well as higher maximum pain scores at every
time point in the placebo group. In both groups,
median pain scores were low (10 mm) after the third
postoperative day. Pain scores immediately after surgery
(0 h) were also low in the capsaicin and placebo group
(median, 12.0 vs 13.5) (P  0.77) and after 4 h (median,
6.5 vs 8.0) (P  0.85), demonstrating the efficacy of the
bupivacaine block in reducing pain from the operation.
The effect of ALGRX 4975 on the VAS scores versus
placebo, and incorporating intersubject variability,
was modeled using NONMEM, as described in Ap-
pendix. Models selectively examined the influence of
capsaicin on VAS score each day after surgery. The
optimal model demonstrated an analgesic effect of
ALGRX 4975 on days 0, 1, 2, 3, and 4 and some
residual effect until the end of the study (change
2LL  204, P  0.0001). The parameters of the final
model are shown in Table 2. Figure 3 shows the
individual modeled VAS score for both groups using
the final model. The goodness of fit can be observed in
Figures 3C and D. The typical population curves (Fig.
3E) demonstrated the analgesic effect of ALGRX 4975
on the VAS scores on days 0, 1, 2, and 3. After day 3,
both groups had very little pain. Nevertheless, there
was a slight, but statistically significant (P  0.014),
transient increase in pain in the subjects receiving
capsaicin, which can also be seen on very close inspec-
tion of Figure 1.
Supplemental tramadol was used by four patients
in the capsaicin group (a group total of 19 tablets) and
by 3 in the placebo group (a group total of 22 tablets).
All tramadol tablets were administered during the
first five postoperative days, consistent with the
greater levels of pain during this time period.
Safety Analysis
No adverse events rated as serious or severe were
seen throughout the study period (Table 3). Eight
(40%) cases of transient increases of aspartate amino-
transferase to levels slightly above normal range were
seen in the capsaicin patients versus 3 (14%) in the
placebo group. The increases were just above the normal
range (10–45 U/L) except in one patient (105 U/L).
Alanine aminotransferase and alkaline phosphatase in-
creases above normal were seen in the capsaicin or
placebo group in 2 versus 1 patients and in 0 versus 1
patient, respectively (Table 4). All tests were normalized
during the followingweek.Wound infection was seen in
2 (10%) patients in the capsaicin group and none in the
placebo group. Postoperative nausea was reported by 4
(20%) patients in the capsaicin group versus 1 (5%) in the
placebo group, dizziness in 5 (25%) versus 3 (14%), and
headache by 6 (30%) versus 2 (10%). All except one
patient in the capsaicin group with wound infection
exhibited normal wound healing at week 2. Laboratory
tests showed one case of urine positive for blood in each
group and one case of bilirubin (placebo); however, the
findings could not be reproduced the next day. No
clinical relevant changes in ECG, heart rate, or arterial
blood pressure were recorded.
DISCUSSION
Capsaicin specifically opens the nonselective cation
channel, TRPV1 (formerly vanilloid receptor 1)18 pre-
dominantly expressed by C-fiber polymodal nocicep-
tors. The resulting flood of cations into the targeted
neuron leads to a transient burst of action potentials,
causing profound stinging, burning, and thermal and
mechanical hyperalgesia,8,10,19–21 followed by revers-
ible desensitization potentially lasting for several
weeks.8,19 The desensitization is due to an intracellular
accumulation of calcium that exceeds the buffering
capacity of the mitochondria of the C-fiber,22 causing
osmotic lysis, resulting in loss of mitochondrial energy
supplies, and disruption of pain (C-fiber) receptor
terminals. During the period of pain-receptor regen-
eration, pain fibers are unable to transmit pain signals,
resulting in a long-term decrease in sensitivity to
noxious, mechanical, and thermal stimulation.9,11
These analgesic effects of capsaicin have primarily
been investigated after topical administration,23–26 but
Table 1. Demographics of 41 Patients Randomized for
Treatment for Postherniotomy Pain by Instillation of 1000 g
Ultrapure Capsaicin (ALGRX-4975) or Placebo
Capsaicin
(n  20)
Placebo
(n  21)
Preoperative pain
median (range)
Rest 0 (0–5) 0 (0–16)
Activity 0 (0–5) 0 (0–58)
Age, mean (yr) 50.7 49.5
Body mass index, mean
(kg/m2)
25.0 23.9
Anesthesia time (mean
min, sd)
77.4 (16.5) 74.3 (16.8)
Surgery time (mean
minutes, sd)
46.9 (9.6) 46.8 (14.1)
Ibuprofen use during the
first week (mean no.
tablets, sd)
20.8 (3.4) 21.2 (1.8)
paracetamol use during
the first week (mean
no. tablets, sd)
54.1 (3.7) 54.3 (5.5)
Pain at rest and during activity was scored after lying down for 10 min and immediately after
sitting up using the abdominal muscles rather than the arms. All subjects were Caucasian
males.
Ibuprofen tablets  600 mg, Acetaminophen tablets  500 mg.
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topical treatment requires repetitive application and
can be painful when administered.
When analyzing the primary and secondary end-
point of average pain during the first week and the
whole study (28 days) using a classical Wilcoxon’s
signed rank test, the observed differences did not
reach statistical significance, despite a visually obvi-
ous difference in the raw data (Fig. 1). The likely
explanation was insensitivity of the statistical model
to the repeated measures design of the study data,
which permits differentiation of intersubject from in-
trasubject variability. To detect if capsaicin influences
Figure 1. Individual (dashed line) and median (solid line) visual analog scale (VAS) pain scores in the placebo (A) and ALGRX
4975 (B) group for the entire time course of the study. C–F shows a detailed view of the study period.
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the VAS trajectory for each patient compared with
placebo, we developed a NONMEM pharmacody-
namic model for VAS versus time, similar to that used
by Flood and Daniel.27 The NONMEM analysis dem-
onstrated an analgesic effect of capsaicin on days 0, 1,
2, and 3, but with slightly higher pain scores on days
4 and 5.
However, when evaluating to the differences in
typical curves (Fig. 3), we have to admit that although
significant, the absolute decrease in VAS score is not
that large. However, it would be wrong to dismiss
purified capsaicin as a potential perioperative analge-
sic since the duration of pain relief for the primary
end-point was chosen from results from experimental
studies suggesting a longer analgesic effect9 and as-
suming the presence of sufficient pain to adequately
compare the capsaicin treated versus the placebo
patients. Both explanatory post hoc analyses (AUC
using nonparametric statistics and NONMEM)
showed that wound instillation of purified capsaicin
was superior to placebo as an add-on analgesic
therapy for the first 3–4 days after groin hernia repair.
The negative result on the primary and secondary
end-points are attributable to the unexpected low VAS
pain score of around 10 mm (0–100 mm Scale) beyond
the third postoperative day. Given the low VAS score
in both treatment groups, it is clear that there was
insufficient remaining pain to provide more test sen-
sitivity. Postoperative pain after hernia repair was
adequately addressed by the concomitant pain medi-
cations of acetaminophen and ibuprofen during the
rest of the first week beyond the third day after
surgery. The measurable postsurgical pain associated
with this procedure does not extend to 30 days.
No severe AEs were observed during the study
period; however, slight increases in aspartate ami-
notransferase levels above the normal range were
seen more often in the purified capsaicin group
compared with controls, and all increases were
Figure 2. Detailed distribution of vi-
sual analog scale (VAS) pain scores
during the first 4 days in patients
with wound instillation of capsaicin
(n  20) or placebo (n  21) during
groin hernia repair. Horizontal bars
represent median pain scores, boxes
represent the 25th and 75th percentile
range, and T-bars the 2.5th and 97.5th
percentile range. Outliers are not
shown.
Table 2. NONMEM Parameters for the Best Fitting Model
Model parameters VAS
TV, placebo day 0 17.1
TV, placebo day 1 26.3
TV, placebo day 2 21.8
TV, placebo day 3 18.2
TV, placebo day 4 13.2
TV, placebo day 4 5.21
TV, capsaicin effect day 0 32%
TV, capsaicin effect day 1 26%
TV, capsaicin effect day 2 23%
TV, capsaicin effect day 3 16%
TV, capsaicin effect day 4 13%
TV, capsaicin effect day 4 56%
CV for all TV 87%
Residual error (sd) 7.11
TV, placebo  typical population visual analog scale (VAS) score in the placebo group for a
specific day; TV capsaicin effect  percent difference from placebo VAS attributable to
ALGRX-4975, whereby a negative value means a lower VAS score compared with TV; CV 
coefficient of variation; SD  standard deviation.
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normalized within the following week. The aspar-
tate aminotransferase elevations are in contrast to
the previously reported studies of purified capsaicin
where there were no treatment-related effects on
laboratory safety variables.12,13 However, the rela-
tively small sample size was not powered to assess
AEs.
The potential for an algesic response to capsaicin is
well described in human studies of intradermal ad-
ministration of capsaicin.8,9,20,28 This response gener-
ally occurs when capsaicin first contacts the target
tissue during its initial contact with TRPV1 receptors,
immediately followed by desensitization of the TRPV1
receptors, resulting in analgesic response. The lack of
Figure 3. NONMEM modeling details. A, B shows the individual post hoc Bayesian predicted visual analog scale (VAS) pain
scores from the best fitting model for the placebo (A) and ALGRX 4975 (B) group. C, D shows the individual measured versus
predicted VAS scores from the best fitting model for the placebo (C) and ALGRX 4975 (D) group. E, the typical population
predicted VAS scores by the best fitting model versus time for placebo and ALGRX 4975.
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report of pain on application of capsaicin in this study
is likely attributable to its intraoperative use while
patients are under anesthesia. The slightly higher VAS
scores in the capsaicin group from day 4–5 could be
interpreted as the development of hyperalgesia. How-
ever, we do not believe this for the following reasons:
First, the pain scores were very low compared with
what is normally seen from capsaicin-induced hyper-
algesia and judging from the AEs reported, hyperal-
gesia was not a specific finding in capsaicin-treated
patients compared with controls. However, the short-
and especially long-term effect of capsaicin instillation
Table 3. Adverse Events (AE) Recorded the First 4 Postoperative Weeks in 41 Patients Randomized for Treatment for
Postherniotomy Pain by Instillation of 1000 g Ultrapure Capsaicin (ALGRX-4975) or Placebo
Adverse event
No. of patients
Mild Moderate Severe
Capsaicin
(n  20)
Placebo
(n  21)
Capsaicin
(n  20)
Placebo
(n  21)
Capsaicin
(n  20)
Placebo
(n  21)
Blood pressure increased 2 0 0 0 0 0
Dizziness 4 1 2 1 0 0
Fatigue 1 0 0 1 0 0
Hematoma 2 1 0 1 0 0
Headache 3 0 3 2 0 0
Skin hypoesthesia 0 0 19 17 0 0
Skin hyperalgesia 0 0 12 9 0 0
Postoperative infection 1 0 1 0 0 0
Abnormal wound healing 0 0 1 0 0 0
Postoperative nausea 1 1 3 0 0 0
Operative hemorrhage 0 1 0 0 0 0
Postoperative hematoma 16 19 3 1 0 0
Postoperative skin reaction 11 17 4 3 0 0
Urine positive for blood 1 1 0 0 0 0
Urine positive for bilirubin 0 1 0 0 0 0
The numbers in each column cannot be added because a subject may have had more than one AE. Hypoesthesia and hyperalgesia was assessed at 1 wk follow-up by stimulation with a von
Frey fiber (Semmes-Weinstein monofilaments, Stoelting, IL, USA; nominal buckling 588.2 milliNewton).
Table 4. Changes in Liver Enzymes in 41 Patients Randomized for Treatment for Postherniotomy Pain by Instillation of 1000 g
Ultrapure Capsaicin (ALGRX-4975) or Placebo
Capsaicin (n  20) Placebo (n  21)
Preoperative
1 week
postoperative
Change
from
baseline Preoperative
1 week
postoperative
Change
from
baseline
Aspartate aminotransferase
(U/L) (normal range,
10–45 U/L)
Mean 28.9 47.3 16.8 25.5 31.7 6.1
sd 11.6 25.7 22.0 10.1 12.6 10.5
Min 11 12 6 12 12 22
Median 28.5 47.5 10.0 22.0 27.0 6.0
Max 54 105 77 48 54 25
Alanine aminotransferase
(U/L) (normal range,
10–40 U/L)
Mean 26.2 37.7 11.5 28.3 31.0 2.7
sd 6.1 18.6 16.4 14.0 14.7 10.5
Min 17 19 7 17 18 35
Median 26.5 34.5 7.0 24.0 26.0 2.0
Max 39 91 63 48 85 20
Alkaline phosphatase (U/L)
(normal range, 20–70
U/L)
Mean 57.7 56.1 1.6 69.0 70.7 1.7
sd 12.8 10.6 4.9 15.6 17.3 21.4
Min 28 34 10 33 45 17
Median 58.0 54.5 3.0 67.0 67.0 3.0
Max 80 92 6 96 121 98
U/L  units per liter; SD  standard deviation; min  minimum value; max  maximum value.
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on sensory functions needs to be investigated in future
studies.
Purified capsaicin may be valuable for periopera-
tive use if analgesia lasting a couple of days can be
confirmed from other surgical models. Preliminary
evidence for such an effect is only available from
buniectomy.12 However, other nonsurgical pain stud-
ies (intermetatarsal neuroma, lateral epicondylitis,
and knee osteoarthritis) support the long-term analge-
sic effect of a purified capsaicin injection.13–15 Similar
to the bunionectomy study,12 we successfully avoided
the initial intense pain after purified capsaicin admin-
istration seen in other studies,13–15 by first administer-
ing a local anesthetic.
The ideal regimen for the treatment of postopera-
tive pain should target the pain at its origin, be of
sufficient duration, have only local effects, be easy to
administer, usable in ambulatory settings, cost-
effective, and available to all patient categories. Un-
fortunately, such a regimen does not yet exist. In groin
hernia repair, several techniques are used to diminish
acute postoperative pain, but none is ideal.7 Limita-
tions include techniques that rely on single-dose
wound injection of local anesthetics and those that are
only effective for 4–6 hours, as well as the use of
continuous wound perfusion with local anesthetics,
which is costly.29–32
In conclusion, instillation of purified capsaicin re-
sulted in superior analgesia to placebo with regards to
average pain during the first 3–4 postoperative days
after inguinal herniotomy. Future studies should ad-
dress the potential use of capsaicin as a single treat-
ment modality, in combination with a systemic rescue
analgesic, in surgical models with intense and pro-
longed postoperative pain.
APPENDIX: THE NONMEM ANALYSIS AND CONTROL FILE OF
THE FINAL MODEL
For the parameters, interindividual variability was
modeled using a constant coefficient of variation
model,
i  TV  (1  i)
where i refers to the individual value of the param-
eter, TV is the typical value of the parameter, and  is
a normally distributed random variable with mean
zero and a variance of 2 individual variability is
reported as , the standard deviation (sd) of  in the
log domain, which is approximately the coefficient of
variation in the standard domain. Residual intraindi-
vidual variability was modeled using a standard ad-
ditive error model,
DV
obs
 DV
exp
 	
where DVobs refers to the observed dependent vari-
able, and DVexp refers to the predicted dependent
variable, 	 is normally distributed random variable
with mean zero and variance 
2. The objective func-
tion for the analysis was 2 log likelihood (2LL).
The possible therapeutic effect of capsaicin on the VAS
score was modeled as a proportional effect (j),
i  TV  (1  i)  (1  j)
A different i was analyzed per day of therapy.
However all i’s share the same i. Individuals are
either above or below the typical (TV) VAS score
(that’s the “repeated measures” part of the analysis).
For each day of therapy, an additional effect j on the
VAS score by capsaicin can be added or not. This
additional effect for a specific day of therapy is
significant compared with placebo if the difference in
2LL exceeds 3.84 when adding 1 parameter as a
nested models (P  0.05, 2 test, 1 degree of freedom).
Various models were tested with a similar and
different additional effect per therapeutic day
(meaning a similar j among days or a different j
among days). In the placebo group, j is always
zero.
The control file of the best-fitting model
$PROB Anesiva VAS Scores, Separate Drug Effect
Each Day
$DATA vas.data.txt
$INPUT ID TIME POD VAS  DV TRT AGE
$PRED
IF (POD.EQ.0)
TYTHETA(1)*(1ETA(1))*(1THETA(7)*TRT)
IF (POD.EQ.1)
TYTHETA(2)*(1ETA(1))*(1THETA(8)*TRT)
IF (POD.EQ.2)
TYTHETA(3)*(1ETA(1))*(1THETA(9)*TRT)
IF (POD.EQ.3)
TYTHETA(4)*(1ETA(1))*(1THETA(10)*TRT)
IF (POD.EQ.4)
TYTHETA(5)*(1ETA(1))*(1THETA(11)*TRT)
IF (POD.GT.4)
TYTHETA(6)*(1ETA(1))*(1THETA(12)*TRT)
IPRED  TY
Y  IPRED EPS(1)
$THETA
(0, 20, 100) ; Theta 01: POD 0
(0, 32, 100) ; Theta 02: POD 1
(0, 26, 100) ; Theta 03: POD 2
(0, 23, 100) ; Theta 04: POD 3
(0, 19, 100) ; Theta 05: POD 4
(0, 7, 100) ; Theta 06: POD 4
0.1 ; Theta 07: Effect on POD0
0.1 ; Theta 08: Effect on POD1
0.1 ; Theta 09: Effect on POD2
0.1 ; Theta 10: Effect on POD3
0.1 ; Theta 11: Effect on POD4
0.1 ; Theta 12: Effect on POD4
$OMEGA 0.75 ; Between subject variability
$SIGMA 50 ; Residual variability
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$ESTIMATION MAX  1000 PRINT  1 NOABORT
METHOD  1 SIG  3
$TABLE ID TIME POD TRT AGE IPRED
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